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Available online 18 March 2008Plasma triglyceride (TG) and apoAV levels are reported to be positively correlated, yet SNPs deﬁning haplotype
APOA5⁎2 have consistently shown association with elevated plasma triglyceride (TG) but not plasma apoAV
levels. We previously reported that individually −1131TNC, −3ANG and +1891TNC did not inﬂuence luciferase
activity or in vitro translation efﬁciency. To investigate the combined effect of these SNPs additional constructs
were examined. Compared to the wildtype −1131T/−3A/+1891T (TAT), the triple rare allele construct −1131C/
−3G/+1891C (CGC) conferred 46% lower luciferase activity (pb0.0001), showing these SNPs are acting co-
operatively. Although only these two combinations occur in vivo, we experimentally altered the TAT construct
one site at a time; −3G (TGT) had the largest effect (94% lower luciferase), with lesser effects from CAT
(−77%) and TAC (−70.3%) (all pb0.0001). Deletion constructs excluding one site at a time showed that −3G/
1891C ( –GC) in combination, compared to −AT, was having the largest effect on luciferase activity (−59%,
p=0.055). Using sequence homology and EMSA analysis no transcription factor binding at −1131 or +1891
was identiﬁed, though +1891 lies within a putative mRNA stability motif. Taken together, these data identify
−3ANG in the Kozak sequence as functional, affecting translation initiation and driving the haplotype effects,
while showing interaction with +1891TNC and to a lesser extent −1131TNC. A paradox arises since these
results predict that APOA5⁎2 will lead to reduced apoAV with concomitant reduced LPL activation or
lipoprotein-receptor interaction, resulting in higher plasma TG levels. We conclude that APOA5 expression,
and not circulating plasma apoAV levels, is causatively associated with plasma TG levels.
© 2008 Elsevier B.V. All rights reserved.Keywords:
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APOA5 encodes a 366 amino acid protein, apolipoprotein (apo)AV,
expressed in the liver [1] and present on chylomicrons (CM), VLDL and
HDL, but not on IDL, LDL or lipoprotein particle-free plasma,
suggesting that VLDL containing apoAV is cleared before conversion
into these lipoproteins [2]. APOA5 expression is tightly regulated by a
number of transcription factors including a member of the nuclear
hormone receptor super-family. APOA5 is highly up-regulated by
PPARα [3], the farnesoid X receptor (FXR) [4] and HNF-4 [5]. APOA5 is
also down-regulated by insulin via the PI3K signalling pathway, which
modulates the binding of USF1 to the APOA5 promoter [6].
Variation in APOA5 has been associated with effects on plasma
triglyceride and to a lesser extent HDL levels [reviewed in [7,8]]. Seven
common APOA5 SNPs deﬁne three common haplotypes; the common
haplotype, APOA5⁎1 is deﬁned by all wildtype alleles, APOA5⁎2 carries
rare alleles of −1131TNC (rs rs662799), −3ANG (rs651821), 751ANGar Genetics, Department of
, 5 University Street, London
6212.
l rights reserved.(rs2072560) and +1891TNC (rs2266788). Since there is 100% LD
amongst these SNPs they only occur in the combinations −1131T/−3A/
1891T or −1131C/−3G/1891C. APOA5⁎3 carries the rare allele of
c.56CNG (rs3135506) alone on a wildtype background [9]. Functional
studies on c.56CNG showed that the amino substitution S19W in the
signal sequence, resulting from this base change, affects signal peptide
function with the W19 protein showing 50% less secretion in an in
vitro assay [10]. By contrast, testing individually the effects of the
APOA5⁎2 SNPs on gene expression using a luciferase reporter gene
assay, −1131C, compared to −1131T, showed 15% non-signiﬁcant lower
expression [10], supporting a previous report that this base change
was not functional [4], while +1891TNC also showed no effect on in
vitro expression [10]. The −3ANG occurs in the Kozak sequence of
APOA5, a motif from −6 to −1 which affects translation [11], but this
change also did not signiﬁcantly affect functionality in an in vitro
reticulocyte transcription/translation assay of apoAV. In constructs
incorporating sites −1131TNC and −3ANG, luciferase activity was only
16% lower in 1131C/−3G compared to 1131T/−3A (p=0.33) [10].
Alleles −1131C and −3G have consistently been associated with
higher plasma TG levels, an effect seen in all ethnic groups [12–16].
While in Caucasians and Indian Asians there is strong linkage
disequilibrium with APOC3 SNPs, within the same gene cluster on
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study of Caucasians we proposed that the association of APOA5
−1131TNC with plasma TG levels could reﬂect this LD with APOC3 SNP
as suggested by haplotype analysis across the cluster [13]. However, in
re-analysing this data [13] using multiple regression analysis, both
APOA5 −1131TNC and APOC3 1100CNT remained in the model, sug-
gesting signiﬁcant and independent effects on TG levels (see
Supplementary table).
In transgenic and knockout animal studies apoAV levels are
inversely related to plasma TG levels. Compared to wildtype mouse
the homozygous APOA5 transgenic has 70% lower plasma TG levels
and the apoa5 knockout has 400% higher TG levels [1]. The same
relationship was reported in a young boy homozygous for the rare
APOA5 Q148X truncation, with no detectable apoAV and TG levels
N50 mmol/l [18]. Recently ELISAs for measuring plasma levels of
apoAV have been developed [19,20] and several studies reported a
counter-intuitive positive correlation between plasma apoAV levels
and plasma TG levels [21–24]. This is the paradox that we have tried to
unravel by undertakingmore in-depth functional analyses of APOA5⁎2
SNPs. In this paper we report the functional interaction between the
−1131TNC, −3ANG, and +1891TNC alleles in determining gene expres-
sion in vitro, and relate this to the relationship between apoAV and TG
levels.
2. Materials and methods
2.1. Materials
Oligonucleotides were from MWG-Biotech, UK. Vectors used in the experimenta-
tion, pGLbasic and the pGEM-T vector system (TM042), as well as the Dual luciferase
assay system (TM040) were all obtained from Promega, UK. BigDye Terminator v3.1
sequencing kit was obtained from Applera, UK. Restriction enzymes were obtained
from New England Biolabs. Illustra, DNA and Gel Band Puriﬁcation kit, was supplied by
GE Healthcare, UK. Lipofectamine 2000 was obtained from Invitrogen, UK. NE-PER
Nuclear and Cytoplasmic Reagents Kit and the Chemiluminescent Nucleic Acid
Detection Module were from Pierce, USA and the Complete Protease Inhibitor was
supplied by Roche, UK.
2.2. Functional studies of variants compromising haplotype APOA5⁎2
To study the functionality of the −1131TNC SNP in the promoter, the −3ANG SNP in
the Kozak sequence as well as the +1891TNC in the 3′UTR, different constructs were
made. For the −1131TNC variant, a 665 bp fragment was ampliﬁed by PCR from DNAFig. 1. Schematic representation of pGL3 basic constructsfrom individuals with known −1131TT or −1131CC genotype. The fragment ranged from
position −1177 to −512 using the original numbering of Olivier et al. [9]. Oligonucleo-
tides were designed with Acc65I at the 5′end of the forward oligonucleotide and BglII at
the 5′end of the reverse oligonucleotide. In addition, CGG and GA tails were introduced
at 5′ends of forward and reverse oligonucleotides. Oligonucleotides were as follows:
forward primer, 5′ CGG GGTACC AGAGGCCCTGCGAGTGGAGTT 3′; reverse primer, 5′ GA
AGATCT TGCTCACCTGCTCACGTCTGG 3′.
The fragment which incorporated both, the −1131 and the −3 sites, ranged from
position −1177 to −1 (fragment 1176 bp). Oligonucleotides were designed with Acc65I
sites at their 5′end of the forward oligonucleotide and BglII at the 5′end of the reverse
oligonucleotide. Again, CGG and GA tails were introduced at the 5′ends of forward and
reverse primers. Oligonucleotides were as follows: forward primer, 5′ CGG GGTACC
AGAGGCCCTGCGAGTGGAGTT 3′ and reverse primer −1131T/−3A, 5′ GA AGATCT
TCTGCTCTGAGAAGACAGGTGG 3′ and −1131C/−3G, 5′ GA AGATCT CCTGCTCTGAGAAGA-
CAGGTGG 3′.
For the +1891TNC in the 3′UTR, an 816 bp fragment was ampliﬁed by PCR from DNA
of individuals with known +1891TT or +1891CC genotype. The fragment ranged from
+1752 to +256. Oligonucleotides were designed with XbaI sites at the 5′end of the
forward oligonucleotide and HpaI at the 5′ends of the reverse oligonucleotide. In
addition, GG and CG tails were introduced at the 5′end of forward and reverse
oligonucleotides. Oligonucleotides used were as follows: forward primer, 5′ GC TCTAGA
GGCCCATTCCCAGCTCCTTGT 3′; reverse primer, 5′ CGG GTTAAC TGTGCTTTGGGGA-
TAGTGGTGAGG 3′. The ampliﬁcation conditions were: 95 °C for 5 min followed by
30 cycles of 95 °C for 1 min, 53 °C for 1 min, 72 °C for 1 min, ending with 72 °C for 5 min.
PCR products were TA-cloned into pGEM-T vector system (TM042) following the
manufacturer's conditions (Promega, UK) and subsequently cloned into pGL3 basic
vector (Promega, UK). The constructs were conﬁrmed by sequencing with Applera
BigDye Terminator v3.1 sequencing kit on an ABI377 automated sequencer. The
combined constructs (referred to as TAT for the construct containing all common SNPs
or CGC for the construct with all mutant SNPs) were created by cloning the fragments
which incorporated the −1131 and the −3 sites into Acc65I and BglII sites and the +1891
fragment into HpaI and XbaI sites of the pGL3 basic vector (Promega, UK).
For the different combinations (TGT, TAC, CAT, CAC, TGC and CGT; mutant SNPs
underlined) restriction sites were used to cut the desired fragments (see Fig. 1). The
fragments were run on 1.5% agarose gels the bands excised and puriﬁed using Illustra,
DNA and Gel Band Puriﬁcation kit, GE Healthcare, before re-ligation in the desired
combination into pGL3 basic and conﬁrmation by sequencing.
To examine further which one of the three a SNPs was responsible for potential
differences between constructs TAT and CGC, “deletion” constructs were created
excluding one site at a time. For this purpose, different constructs were used as
templates and one SNP at a time was removed by restriction enzyme digest (for the
−1131 fragment, Acc65I and BglII; for the −1131 and −3 fragments, Acc65I and BglII; for
the −3 fragment, AatII (naturally occurring site in sequence) and BglII and for the +1891
fragment HpaI and XbaI). The fragments were run on 1.5% agarose gels the bands
excised and puriﬁed using Illustra, DNA and Gel Band Puriﬁcation kit, GE Healthcare,
before re-ligation in the desired combination into pGL3 basic and conﬁrmation by
sequencing. Constructs were created as followed: –GC, C–C, –AT and T–T. Results from
the TA– and CG– were taken from the previous publication [10].including the APOA5 promoter and 3′UTR fragments.
Fig. 2. a, b. Effects of the APOA5 promoter and 3′UTR fragments including sites
−1131TNC, −3ANG (1176 bp promoter sequence) and +1891TNC (816 bp 3′UTR
sequence), in different combinations, on relative luciferase (Luc) activity, compared to
wildtype construct TAT (set at 100). Data were corrected for transfection efﬁciency.
Results represent data from 30 repeat experiments each with 8 replicates for TAT vs.
CGC, 5 repeats each with 8 replicates for the rest, from at least two different DNA
preparations (bars=SEM). Data for a and b are identical but the comparisons changed.
Fig. 3. Pair-wise comparison of deletion constructs with one site missing in each
construct on relative luciferase (Luc) activity. Mutant construct compared to the
wildtype construct in each case. Data were corrected for transfection efﬁciency. Results
represent data from 3 repeat experiments each with 8 replicates from two different
DNA preparations (bars=SEM).
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Promega, UK). Brieﬂy, Huh7cells, from a human hepatoma cell line, were used for
transient transfection for all variants. Huh7 cells in 96-well format (4×104 cells/well)
were transiently transfected with 200 ng of the appropriate plasmid or control vector,
1 ng of pRL-TK co-transfector, and 0.5 µl of Lipofectamine 2000, and the cells were lysed
48 h after transfection. For the TATand CGC constructs, results represent themean of 30
experiments each performed in sets of 8 repeats/well. The different combinations (TGT,
TAC, CAT, CAC, TGC, CGT) represent the mean of 5 experiments, each replicated 8 times/
well and the “deletion constructs” represent the mean of 3 experiments, each
performed in sets of 8 repeats/well. Statistical analysis was performed using SPSS
version 12.0.1 (SPSS, Chicago, IL) and an independent sample T-test.
2.3. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were obtained from unstimulated and IL-6-stimulated Huh7 cells
using the NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit (Pierce, USA) as
described by the manufacturer, with the addition of Complete Protease Inhibitor
(Roche, UK) to buffers CER I and NER I. EMSA probes for the APOA5 genomic sequences:
−1131: 5′-GCAAATCT[C/T]ACTTTCGC-3′
−3: 5′-CTCAGAGCAG[G/A]TAATGGCAAG-3′
+1891: 5′-GTCTCCTGCA[C/T]ATCCAGCCTC-3′.
Probes were labelled using the Biotin 3′-End DNA Labelling Kit (Pierce, USA) as
described by themanufacturer, and annealed to the complementary labelled oligo. Each
binding reaction consisted of 2 μl 10× binding buffer (100mM Tris, 500mMKCl; pH 7.5),
1 μg p[dI–dC], 200 fmol biotin-labelled DNA, made to a total of 20 μl with H2O, and
incubated at 25 °C for 30 min, followed by the addition of 5× loading buffer.
Competition reactions were carried out with 30 min incubation on ice, prior to addition
of labelled probes, using 100× unlabelled competitor DNA. Samples were loaded on to a6% polyacrylamide gel, and electrophoresed for 150 min at 120 V and +4 °C. Gel
products were transferred to nylon membrane by Southern blot analysis using the
Chemiluminescent Nucleic Acid Detection Module (Pierce, USA).
3. Results
3.1. 751ANG (c.172-43ANG) does not alter function by in silico analysis
The APOA5⁎2 haplotype is deﬁned by four common SNPs in
complete LD, −1131TNC (rs662799), −3ANG (rs651821), +751ANG
(rs2072560) and +1891TNC (rs2266788). However, the functional
potential of the +751ANG was never previously examined. We used
several computerprogrammes to analyse if this SNP in intron2 (c.172-43)
had the potential to affect splicing; http://www.fruitﬂy.org/seq_tools/
splice.html identiﬁes canonical splice sites by neural networking while
http://rulai.cshl.edu/cgiin/tools/ESE3/eseﬁnder.cgi?process=home iden-
tiﬁes potential exonic splicing enhancers (ESE) — SR protein potential
binding sites. There were no potential canonical splice sites or ESEs at
position c.172-43. The possibility of the presence of a transcription factor
binding site was also examined using MatInspector (http://www.
genomatix.de/products/MatInspector/index.html), a transcription factor
search engine, but none was identiﬁed. For this reason no further
experimentation was carried out on this SNP.
3.2. The combined effect of −1131TNC, −3ANG and +1891TNC on luciferase
activity
To testwhether these SNPswhichoccur together as ahaplotypewere
acting co-operatively, constructs were made for transient transfection
into Huh7 cells, including a 1176 bp APOA5 promoter fragment
incorporating positions −1131 and −3, introduced 5′ of the luciferase
gene, and 816 bp of the APOA5 3′UTR, positioned 3′ of luciferase, which
included site +1891 (Fig. 1). As shown in Fig. 2a the relative luciferase
activity of the rare allele combination −1131C/−3G/+1891C (CGC) was
54% lower compared towildtype−1131T/−3A/+1891T (TAT) (pb0.0001),
conﬁrming that the three rare alleles were acting in a co-operative
manner.
To identify the relative contribution of the three sites to luciferase
activity, constructs corresponding to the six other combinations of the
three sites were used to transiently transfect Huh7 cells. None of these
combinations occur in vivo. One out of three wildtype sites (TAT) was
converted to a rare allele, i.e. leaving two wildtype sites in place,
−1131C/−3A/+1891T (CAT), −1131T/−3G/+1891T (TGT) and −1131T/
−3A/+1891C (TAC). As shown in Fig. 2a, all constructs gave signiﬁcantly
lower luciferase levels than wildtype TAT, but TGT had the largest
effect; CAT (−76.7%); TGT (−97%); TAC (−70.3%) (all pb0.0001) and
Fig. 4. EMSA to investigate differential binding abilities of APOA5 variants using IL-6 stimulated nuclear extract. See text for details of probes and binding conditions. Lane 1: Sp1
consensus probe; lane 2: Sp1 consensus probe with excess unlabelled oligo; lanes 3–6: −1131C/T probes with excess unlabelled competitor in 4/6; lanes 7–10: −3A/G probes with
excess unlabelled competitor in 8/10; lanes 11–14: 1891C/T probes with excess unlabelled competitor in 12/14; lane 15: Sp1 consensus sequence with no extract.
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TGT pb0.0001; TAC p=0.035). When two sites of TAT were changed at a
time to rare alleles, leaving only onewildtype site, luciferase levelswere
also highly signiﬁcantly different from wildtype TAT (all pb0.0001),
(CGT (−69.2%), TGC (−70.7%) and CAC (−53%), but nonewas signiﬁcantly
different from CGC (all pN0.05). Thus one or two changes from TAT
lowered luciferase activity signiﬁcantly to the level of themutant CGC or
below, with the −3ANG having the greatest lowering effect. This is more
clearly seen in Fig. 2b.
3.3. Pair-wise effect of −1131TNC, −3ANG and +1891TNC on luciferase
activity
To investigate further the effects of the three SNPs, changes were
made to wildtype TAT or mutant CGC, deleting one site at a time. The
−1131C/−3G (CG–) combination showed 16% lower luciferase activity
compared to −1131T/−3A (TA–) (p=0.37) (see Fig. 3) [10]. It was on the
basis of these results thatwe concluded that in combination −1131TNC/
−3ANGwas not having a strongeffect onpromoter activity. As shown in
Fig. 3, since construct lengthswere different, comparisonwasmade for
each pair, thus for the −1131TNC and +1891TNC constructs, C–C
(−1131C/+1891C) compared to T–T (−1131T/+1891T), showed 23%
lower relative luciferase activity which was not statistically signiﬁcant
(p=0.36), suggesting that this combination, which excluded the −3
site, showed little functional difference in expression. By comparison,
the combined effect of −3ANG together with +1891TNC, –GC had 59%
lower luciferase activity relative to –AT (pb0.055). These results
suggest that the combination of −3G and +1891C is driving the
haplotype effect, but cannot explain it fully. Thus all three sites are
necessary to achieve the overall difference between TAT and CGC.
3.4. Transcription binding sites at positions −1131, −3 and +1891
To investigate if there were any transcription factor binding sites in
the vicinity of −1131, −3 or +1891 which could explain this promoter
effect, MatInspector (http://www.genomatix.de/products/MatInspec-
tor/index.html), a transcription factor search engine, was used. A
putative Oct-1 transcription factor binding site was identiﬁed in silico,
spanning position +1891. No obvious transcription factors mapped at
the other sites. However, using an EMSA, competing labelled −1131T
and −1131C probes, −3A or −3G probes and +1891T and +1891C
probes with excess unlabelled competitor probe no novel bands were
seen. To test if the assay worked, Sp1 was used as a positive control
(Fig. 4). Furthermore, an Oct-1 monoclonal antibody used as a speciﬁc
competitor produced no supershift (data not shown).
4. Discussion
Although the association of APOA5 −1131TNC and/or −3ANG SNPs,
with plasma TG levels has been consistent [7,8], functional assays ofthe haplotype APOA5⁎2 SNPs individually could not provide an
explanation for this association [10]. This current set of experiments
suggests that the functionality of APOA5⁎2 relies on the interaction of
three of the four SNPs, which deﬁne the haplotype and which show
100% LD. This results in a 54% lower luciferase activity by the rare
allele construct CGC compared to the wildtype construct TAT. Because
of this complete LD, no other combinations of these SNPs occur in vivo.
This means that it is not possible to examine their individual asso-
ciation with plasma TG levels or plasma apoAV levels, and hence infer
function separately.
By creating various combinations of the three variant sites, we have
managed to obtain a better understanding of their effects. We
previously showed that individually these SNPs do not have a
statistically signiﬁcant effect on gene expression [10]. Using pair-
wise constructs it is clear that taking any two of the rare alleles in
combination does not signiﬁcantly affect gene expression, and indeed
a large effect is only seen in a three allele construct. However,
compared to the three common allele construct, TAT, the level of gene
expression was even lower than CGC when a single rare site was
present, as in CAT, TGT and TAC, with TGT having the most dramatic
lowering effect. Thus we conclude that while all three variant sites are
contributing to the large overall difference, their contribution is not
equal with the major effect due to the combination of the −3ANG and
the +1891TNC, in addition to some contribution from −1131TNC.
However, since the luciferase assay is an artiﬁcial system, and these
variants are notwithin their normal APOA5 or chromatin environment,
extrapolating to the endogenous milieu must be made with caution.
The −3GNA lies in the Kozak sequence, preceding the initiating
AUG codon, which represents a highly conserved motif in eukaryotes
regulating ribosomal translation [11]. The −3ANG SNP was tested
previously in a reticulocyte transcription/translation assay which
measured the relative amount of apoAV translated from −3A construct
compared to a −3G construct [10]. However, although this assay
speciﬁcally examined apoAV translation, it was not sensitive, and we
reported no difference in translation of apoAV in the presence of the
−3A compared to the −3G Kozak sequence. Also in combination with
−1131TNC (TA– vs. CG–) no signiﬁcant differences were seen [10].
However, by changing the wildtype sites TAT, singly or in pairs, all
changes signiﬁcantly affected luciferase levels, suggesting all three
sites contributed to the difference in TAT vs. CGC, but only in the
context of the whole fragment.
4.1. How can we explain the interaction of the −3ANG and +1891TNC?
The assay used here assesses overall effects on luciferase gene
expression by combining transcription and translation effects. This
indirect but sensitive assay, conﬁrms that the −3ANG in the Kozak
sequence does inﬂuence the amount of luciferase protein produced
and that it is likely to be doing so by affecting translation. Neither in
silico nor in vitro data supported the presence of a nuclear
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surprising since the translationmachinery at the AUG is likely to block
access to a transcription factor [25]. The construct –GC, containing the
−3G together with the +1891C, showed the largest effect on luciferase
activity lowering, suggesting an interaction between these two sites.
While in silico the search engine identiﬁed a putative Oct-1 site
spanning position +1891, in vitro data suggested this was not
functional. An alternative possibility is that changes within the 3′
UTR of the gene may affect mRNA stability. There are several reported
SNPs in the 3′UTR of genes that affect mRNA stability and are
associated with disease phenotypes [26–29]. In vitro studies of PAI2
conﬁrmed that a sequence motif GATAAATCC in the 3′UTR affected
mRNA stability [27]. This motif shares 5/10 sites with the sequence
ﬂanking +1891TNC, CTGCAT/CATCC, thus it might provide an under-
lying mechanism for the +1891TNC effect seen in the whole construct.
Future work is needed to conﬁrm this.
There is a precedent set by the CETP promoter SNPs for functional
interaction [30]. The CETP TaqIB SNP in intron 1 has consistently been
associated with CETP and HDL levels [31–33] yet was considered to be
unlikely to be functional. Three promoter SNPs, −629CNA (rs1800775),
−971GNA (rs4783961) and −1337CNT (rs17368435), in LD with TaqIB,
were identiﬁed, each showing varying associationwith CETP and HDL
levels, yet each alone could not explain the TaqIB association. Using
luciferase reporter constructs, the interaction of these SNPs was
demonstrated. The proposed basis for this was suggested to be a three
dimensional conformational change in the promoter, enabling Sp1/
Sp3:DNA interactions and leading to chromatin remodelling and
transcription repression [30]. We can only speculate on the basis of
the APOA5⁎2 interaction. Our data suggest that the interaction is at the
level of reduced transcription/translation (−3ANG) together with a
reduction in mRNA stability (+1891TNC). The mechanism governing
the contribution of the −1131TNC in the reduction of gene expression
remains to be determined. A functional HNF4 transcription factor
binding site lies close to −1131 [5] and thismight have a small effect on
transcription in an allele-speciﬁc manner in the context of the whole
haplotype.
4.2. The paradox arising from the relationship between apoAV levels,
plasma TG and APOA5 SNPs
The exact function of apoAV remains unclear. Although expressed
primarily in the liver [1], there are very few studies that support a role
for apoAV in the production of TG-rich lipoproteins from the liver [34].
However, apoAV promotes LPL hydrolysis of TG-rich lipoproteins by
stabilising the LPL dimer [35,36]. In addition, apoAV has been shown
to interact with members of the LDL-receptor family and can thus
‘bridge’ TG-rich particles to the receptors for catabolism [37,38].
Transgenic and knockout mouse models suggest an inverse relation-
ship between plasma apoAV and TG levels [1]. Surprisingly, several
studies have reported a positive correlation between plasma apoAV
and plasma TG levels [21–24]. This correlation may be more complex
than it ﬁrst appears and it has been suggested that, after correction for
apoCIII levels, the relationship between apoAV and plasma TG is no
longer signiﬁcant [20].
For S19W (c.56CNG) both molecular modelling and functional
studies conﬁrmed that this substitution alters signal peptide function,
with the W19 showing reduced secretion potential which should lead
to less apoAV secretion from hepatocytes [10]. Again surprisingly W19
has consistently been reported to be associated with higher plasma
apoAV levels [21,22,24], leading Henneman et al. to question the
validity of the functional studies predicting reduced secretion of
apoAV [24]. However, all the functional studies on apoAV suggest an
inverse relationship with plasma TG levels [35–38]. Our current
studies suggest that the functional effect of APOA5⁎2 would lead to a
50% lower apoAV expression, which is in good agreement, for
example, with the 42% higher TG levels seen in −1131CC homozygotescompared to −1131TT individuals [13]. However, paradoxically
−1131TNC is not associated with difference in plasma apoAV levels
in at least 4 studies [21–24].
Before the direct effects on gene expression of these APOA5 SNPs
were demonstrated, their association with TG levels could be
explained by the LD with APOC3 SNPs, since the functionality of
these SNPs is well documented [39,40]. This LD effect would also
explain the lack of association of TG-raising SNPs with detectable
effects on plasma apoAV levels [22]. However these current experi-
ments, together with our re-analysis of the original haplotype data
[13] showing that APOA5 −113TNC and APOC3 1100CNT have
independent effects on plasma TG levels in multiple regression
analysis, make this less likely. Olano-Martin et al. have used a similar
approach to demonstrate that the effect of the APOA5⁎2 haplotype, as
represented by −1131TNC, on fasting TG levels and postprandial
response, was independent of APOC3 variants (in this case the APOC3
3238CNG) using linear regression analysis. Only the −1113TNC
remained in the model, exhibiting an independent association [41].
Recently, the in vivo characterisation, by targeted introduction of
either APOA5⁎2 or APOA5⁎3 into the mouse genome, was undertaken
to test their functional effects in vivo [42]. Interestingly, while
APOA5⁎3 (S19W) mice had three-fold lower human apoAV plasma
levels than wildtype APOA5⁎1 mice, APOA5⁎2 mice had plasma levels
that were not different from APOA5⁎1. The conclusions drawn from
these experiments were that S19W is a functional SNP while the SNPs
deﬁning APOA5⁎2 are not, at least in the milieu of the mouse. These
experiments, however, do not explain why in humans S19W is
associated with higher plasma apoAV levels, and thus do not shed
additional light on the relationship between plasma measures of
apoAV and TG in humans.
The underlying paradox is that observational studies ﬁnd a positive
correlation between plasma apoAV and TG levels but all the functional
studies of apoAV protein and APOA5 variants support an inverse
relationship between apoAV and plasma TG. This inverse relationship
is supported by the APOA5 truncation homozygote with extremely
high plasma TG levels [18]. Thus, in conclusion, taken together, these
functional studies support an inverse relationship between apoAV and
plasma TG levels and raise questions about the relevance of circulating
plasma apoAV as a marker of hypertriglyceridemia.
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